Replies to post #43019 on Biotech Values

[masterlongevity]

not to mention, BIIB also ahs ritucan and BG12 in phase III trials for MS

[DewDiligence]

>With 3 products for MS (Interferon, Tysabri, Daclizumab) is there a risk that BIIB will cannabilize sales of the other two drugs?<

Good companies are always searching for ways to cannibalize their sales!